Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase II pilot study evaluating the safety of a risk-adjusted outpatient-based
approach to lymphoma salvage therapy with VGF (vinorelbine, gemcitabine and pegfilgrastim)
and/or F-GIV (gemcitabine, Ifosfamide, vinorelbine and pegfilgrastim) in combination with
Rituximab (R-VGF/R-F-GIV).